Literature DB >> 31682868

Galectin-3 modulation of T-cell activation: mechanisms of membrane remodelling.

Rebecca C Gilson1, Sachith D Gunasinghe1, Ludger Johannes2, Katharina Gaus3.   

Abstract

Galectin-3 (Gal3) is a multifaceted protein which belongs to a family of lectins and binds β-galactosides. Gal3 expression is altered in many types of cancer, with increased expression generally associated with poor prognosis. Although the mechanisms remain unknown, Gal3 has been implicated in several biological processes involved in cancer progression, including suppression of T cell-mediated immune responses. Extracellular Gal3 binding to the plasma membrane of T cells alters membrane organization and the formation of an immunological synapse. Its multivalent capacity allows Gal3 to interact specifically with different membrane proteins and lipids, influencing endocytosis, trafficking and T cell receptor signalling. The ability of Gal3 to inhibit T cell responses may provide a mechanism by which Gal3 aids in cancer progression. In this review, we seek to give an overview of the mechanisms by which Gal3 alters the spatial organization of cell membranes and how these processes impact on T cell activation.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Galectin-3; Glycolipids; Immunological synapse; Immunotherapy; T cell activation; T cell signalling

Mesh:

Substances:

Year:  2019        PMID: 31682868     DOI: 10.1016/j.plipres.2019.101010

Source DB:  PubMed          Journal:  Prog Lipid Res        ISSN: 0163-7827            Impact factor:   16.195


  15 in total

1.  Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB.

Authors:  Morten Aagaard Nielsen; Kristian Juul-Madsen; John Stegmayr; Chao Gao; Akul Y Mehta; Stinne Ravn Greisen; Tue Wenzel Kragstrup; Malene Hvid; Thomas Vorup-Jensen; Richard D Cummings; Hakon Leffler; Bent Winding Deleuran
Journal:  Front Immunol       Date:  2022-06-24       Impact factor: 8.786

Review 2.  Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.

Authors:  Diego José Laderach; Daniel Compagno
Journal:  Cancers (Basel)       Date:  2021-09-09       Impact factor: 6.575

Review 3.  Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials.

Authors:  Daniel Compagno; Carolina Tiraboschi; José Daniel Garcia; Yorfer Rondón; Enrique Corapi; Carla Velazquez; Diego José Laderach
Journal:  Biomolecules       Date:  2020-05-12

Review 4.  Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development.

Authors:  Aleksandar Arsenijevic; Bojana Stojanovic; Jelena Milovanovic; Dragana Arsenijevic; Nebojsa Arsenijevic; Marija Milovanovic
Journal:  Int J Mol Sci       Date:  2020-07-19       Impact factor: 5.923

5.  Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.

Authors:  Marina Stasenko; Evan Smith; Oladapo Yeku; Kay J Park; Ian Laster; Kwangkook Lee; Sven Walderich; Elizabeth Spriggs; Bo Rueda; Britta Weigelt; Dmitriy Zamarin; Thapi Dharma Rao; David R Spriggs
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

Review 6.  Biomechanics of T Cell Dysfunctions in Chronic Diseases.

Authors:  Sachith D Gunasinghe; Newton G Peres; Jesse Goyette; Katharina Gaus
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 7.  Galectin-3, Possible Role in Pathogenesis of Periodontal Diseases and Potential Therapeutic Target.

Authors:  Milica Velickovic; Aleksandar Arsenijevic; Aleksandar Acovic; Dragana Arsenijevic; Jelena Milovanovic; Jelena Dimitrijevic; Zeljko Todorovic; Marija Milovanovic; Tatjana Kanjevac; Nebojsa Arsenijevic
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

Review 8.  Medawar's PostEra: Galectins Emerged as Key Players During Fetal-Maternal Glycoimmune Adaptation.

Authors:  Ellen Menkhorst; Nandor Gabor Than; Udo Jeschke; Gabriela Barrientos; Laszlo Szereday; Gabriela Dveksler; Sandra M Blois
Journal:  Front Immunol       Date:  2021-12-15       Impact factor: 7.561

Review 9.  Galectins and Ovarian Cancer.

Authors:  Chisa Shimada; Rui Xu; Linah Al-Alem; Marina Stasenko; David R Spriggs; Bo R Rueda
Journal:  Cancers (Basel)       Date:  2020-05-31       Impact factor: 6.639

10.  Galectins for Diagnosis and Prognostic Assessment of Human Diseases: An Overview of Meta-Analyses.

Authors:  Yiting Liu; Hao Meng; Shixue Xu; Xingshun Qi
Journal:  Med Sci Monit       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.